Artelo Biosciences, Inc. (ARTL)
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
$3.64M
Mr. Gregory D. Gorgas M.B.A.
4.00
Solana Beach, CA
Oct 13, 2015
-0.34
$-3.35
2.87
14.58
0.00%
-0.58
-0.01
0.24
0.00
14.58
-39.31%
-37.69%
Similar stocks (11)
Eliem Therapeutics, Inc.
ELYM
MediciNova, Inc.
MNOV
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRBW
Akari Therapeutics, Plc
AKTX
Curis, Inc.
CRIS
Vaccinex, Inc.
VCNX
Pasithea Therapeutics Corp.
KTTA
Fresh Tracks Therapeutics, Inc.
FRTX
Salarius Pharmaceuticals, Inc.
SLRX
Histogen Inc.
HSTO
Similar stocks (11)
Eliem Therapeutics, Inc.
ELYM
MediciNova, Inc.
MNOV
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRBW
Akari Therapeutics, Plc
AKTX
Curis, Inc.
CRIS
Vaccinex, Inc.
VCNX
Pasithea Therapeutics Corp.
KTTA
Fresh Tracks Therapeutics, Inc.
FRTX
Salarius Pharmaceuticals, Inc.
SLRX
Histogen Inc.
HSTO